Biotech startup developing next-generation nanomedicines for neurological applications, with an focus on acute ischemic stroke, Nanomuse's core innovation centers on VCAM-targeted nanocarriers designed to cross compromised brain vasculature and deliver drugs (or mRNA payloads) directly to ischemic tissue, achieving far higher concentration than free drugs and significantly improving efficacy in preclinical stroke models. Addressing immune clearance challenges, Nanomuse incorporates human complement inhibitors into its platform, enhancing safety and biocompatibility. In 2023, the firm was awarded a Phase I SBIR grant of approximately $300,000 from NIH/NINDS to advance this work, including preclinical studies showing promising reductions in infarct volume and improved behavioral recovery. With a lean structurereported as a single-employee operation at the time of awardNanomuse is positioned at the intersection of nanotechnology, drug delivery, and neurology, aiming to expand into broader CNS applications while seeking follow-on funding, partnerships, and potential commercialization pathwa
